

## Special Issue

# Molecular Pharmacology of 5-HT Receptors

### Message from the Guest Editor

In the human central nervous system (CNS) alone, all the serotonin receptor subtypes, with the exception of 5-HT5b, are expressed. LGICs require auxiliary subunits for their trafficking, assembly, and pharmacological modulation. Auxiliary subunits do not form functional homomeric receptors but are reported to assemble with the principal subunits in order to modulate their pharmacological profiles. For example, in the brain, serotonergic 5-HT3B, 5-HT3C, 5-HT3D, and 5-HT3E are reported to assemble with the 5-HT3A subunit to modulate its pharmacological profile. Much research regarding serotonin has been in the area of neuropsychiatric drug discovery in the treatment of affective disorders, where there continues to be an extreme interest in the design of more efficacious pharmaceuticals. With the wealth of structural information obtained in the past twenty years for serotonin GPCRs and LPGCs, this Special Issue focuses on the challenge for modern 5-HT research: structure-guided approaches that eventually lead to neuropsychiatric medications with greater efficacy and fewer side effects.

### Guest Editor

Dr. Caroline Sevoz-Couche  
Sorbonne Université, Paris, France

### Deadline for manuscript submissions

closed (25 January 2022)



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/54585](https://mdpi.com/si/54585)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





# Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)